Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
   
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Pathways
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: News
News
News Search  
Think You Know γ-secretase and p25? Think Again
5 February 2010. There are times in the course of scientific enterprise when researchers must re-evaluate their hypotheses in the face of new, unexpected data. Two papers published this week offer the Alzheimer’s field just those kinds of contrary results. In the February 3 Journal of Neuroscience, researchers from Washington University in St. Louis, Missouri, report that the γ-secretase complex, long assumed to require nicastrin to recognize and cleave amyloid precursor protein, gets by without it. And in a paper posted online by PNAS, scientists from the University of California in Santa Barbara present evidence that p25, long thought to be a hyperactive, tau-phosphorylating cleavage product of p35, has identical kinetics to its parent.

“Science is about observation and about not really accepting your dogma to the degree that it forces you to ignore what is right in front of your own eyes,” said Raphael Kopan, senior author on the Journal of Neuroscience paper. “That is how progress is made.”

No Nicastrin? No Problem
For Guojun Zhao, first author on the Kopan group paper, progress started with an unexpected, unexplainable band on a Western blot. It was the right size for the product of γ-secretase cleavage of Notch, but the cell line he was using lacked nicastrin, thought to be required for the enzyme’s activity.

In addition to Notch receptors, γ-secretase cleaves the amyloid precursor protein (APP), producing toxic Aβ fragments. The enzyme complex contains four proteins: presenilin, nicastrin, Pen2, and Aph1. Presenilin contains the catalytic site. Pen2 and Aph1 are of uncertain, but essential function. And everybody knows that nicastrin provides the substrate recognition site (see ARF related news story on AbstractShah et al., 2005).

But lately, there has been some controversy over nicastrin’s precise contribution. In 2008, researchers from Bart De Strooper’s laboratory at KU Leuven in Belgium reported that nicastrin contributes to maturation of the complex, but not its activity (Chávez-Gutiérrez et al., 2008). Zhao chose to pursue that pesky band.

He added γ-secretase inhibitors to his cells. “And, lo and behold, the band went away,” Kopan said. To further test the enzyme’s activity, Zhao transfected embryonic fibroblasts from a nicastrin-knockout mouse with a γ-secretase substrate. When he treated the cells with protease inhibitors, the cleavage product band intensified. The results suggest that γ-secretase minus nicastrin is active, but the enzyme or its cleavage product are normally degraded by the proteasome. Using protease inhibitors to reveal the cleavage product was the “key trick,” said Michael Wolfe of Harvard Medical School, who was not involved in the research. Without those inhibitors, the cleavage product would be easy to miss. The researchers confirmed their results in a second nicastrin-negative cell line, and with APP instead of Notch as a substrate. Without nicastrin, the cells were able to cleave an APP substrate and release Aβ40 into the media.

“We thought the complex required all four components, and that was that, so I was dubious,” Wolfe said. He was surprised to find the paper convincing, he told ARF. It is difficult to reconcile the current work with past papers suggesting nicastrin is crucial for substrate recognition, but Wolfe suggested nicastrin might assist in substrate recognition without being absolutely necessary. “We need to revise our thinking about how the enzyme is assembled,” Kopan said. The authors suggest that nicastrin acts to stabilize the enzyme. “It is still essential, but not for the function we thought,” Kopan said. He suggested that working with a three-part complex might simplify biochemical and structural studies. Nicastrin is the largest component of the complex, and he suggested crystallizing three proteins might be easier than four, for example.

P25 Not More Potent
Another cleavage product relevant to neurodegenerative disease is p25. Its parent is the longer p35, a membrane-bound regulatory subunit of Cdk5. Cdk5/p35 is an essential neural kinase. When Cdk5 instead hooks up with p25, a cytoplasmic proteolysis product, the two wreak havoc, phosphorylating tau, causing DNA damage, and promoting neurodegeneration. The p25 form accumulates in the brains of people with AD and, because it is not readily degraded, promotes constitutive activity of Cdk5 (Patrick et al., 1999). Cdk5/p25 has also been linked to Parkinson disease (Smith et al., 2003) and amyotrophic lateral sclerosis (Nguyen et al., 2001).

“There is a common belief in the field that Cdk5/p25 is actually hyperactive,” said John Lew, senior author on the PNAS study with first author Dylan Peterson and colleagues. A 2002 in vitro analysis by a group in Tokyo, Japan, appeared to support this theory; the researchers found differential enzyme kinetics between the p25 and p35 forms (Hashiguchi et al., 2002).

However, Peterson and Lew doubted those results. When they repeated in vitro analysis of the enzyme kinetics, collecting more extensive data, they found that p25 and p35 were statistically the same on every parameter. “This is done by direct comparison of the two enzymes, purified, with nothing else interfering,” Lew said. Kinetic parameters and phosphorylation sites, determined by nuclear magnetic resonance, matched with both histone H1, Cdk5’s best-known substrate, and tau. Why the difference from the 2002 results? “There is really no good explanation,” Lew said. “I think it is just a matter of different hands.” He noted that he cannot rule out cellular factors, not present in the in vitro experiments, that could influence p25 activity.

Researchers must now think of another reason that p25 causes trouble, Lew said. “P25 is a much more stable protein, with a longer half-life,” noted Li-Huei Tsai of MIT, but Lew doubts protein levels are the answer, and said p25 and p35 steady-state levels are similar. Localization could also make a difference: While p35 resides in the cell membrane, p25 is free in the cytoplasm, where it is likely to encounter different substrates. One important substrate, Tsai suggested, is histone deacetylase 1 (HDAC1). Cdk5/p25 inhibits HDAC1, leading to DNA breaks, cell cycle disruption, and neurodegeneration (see ARF related news story on Kim et al., 2008).

“In a way, I am not surprised at all,” Tsai said. “This happens all the time in science.” Together, these two papers show the importance of keeping an open mind. “When nature throws hints in your path, you should pay attention,” Kopan said.—Amber Dance.

References:
Zhao G, Liu Z, Ilagan MX, Kopan R. Gamma-secretase composed of PS1/Pen2/Aph1a can cleave Notch and amyloid precursor protein in the absence of nicastrin. J Neurosci. 2010 Feb 3;30(5):1648-56. Abstract

Peterson DW, Ando DM, Taketa DA, Zhou H, Dahlquist FW, Lew J. No difference in kinetics of tau or histone phosphorylation by CDK5/p25 versus CDK5/p35 in vitro. Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):2884-9. Abstract

 
Comments on News and Primary Papers
  Primary Papers: Gamma-secretase composed of PS1/Pen2/Aph1a can cleave notch and amyloid precursor protein in the absence of nicastrin.

Comment by:  Lucia Chavez-Gutierrez
Submitted 5 February 2010 Posted 5 February 2010

Zhao et al. present a novel and interesting set of findings that shed light on one of the most intriguing features of the γ-secretase enzyme: its dependence on the formation of a high-molecular-weight complex. This study provides further support for the involvement of nicastrin in assembly, maturation, and stabilization of the γ-secretase complex rather than in substrate recognition or as a crucial component for catalytic activity of the complex. The results presented in this article are in accordance with our previously published study (Chavez-Gutierrez et al., 2008) and our current working hypothesis for γ-secretase.

Remarkably, this report shows that a nicastrin-less γ-secretase complex, consisting of PS1/APH1a/PEN2, displays indistinguishable catalytic properties relative to the mature γ-secretase (containing nicastrin). Moreover, this nicastrin-less complex also requires ectodomain shedding of the substrate prior to catalysis, demonstrating that nicastrin does not participate in the recognition of...  Read more

Comments on Related Papers
  Related Paper: Analysis of the gamma-secretase interactome and validation of its association with tetraspanin-enriched microdomains.

Comment by:  Lawrence Rajendran
Submitted 23 October 2009 Posted 23 October 2009

Another beautiful work on the biochemistry of γ-secretase complex from the group of Bart de Strooper.

This connection to tetraspanins offers key insights into the "raft" association of γ-secretase. The raft link to APP processing is very weak and highly contended. Lipid rafts are dynamic platforms that could be, to a large extent, biochemically purified by detergent extraction methods.

Typically Triton X-100 (in concentration ranging from 0.3 percent to 1 percent) insoluble fractions of membranes represent the raft fraction. However, tetraspanin microdomains (TEM) differ from the "canonical" rafts in that these are triton soluble but are insoluble to other milder detergents such as CHAPS or BRIJ. This study clearly demonstrates a direct link between tetraspanin microdomains and γ-secretase, thereby providing evidence that much of the γ-secretase activity is probably confined to tetraspanin microdomains.

An (obvious) interesting question is, How about Notch cleavage? While γ-secretase cleavage of β-CTF seems to depend on its interaction...  Read more


  Related Paper: Analysis of the gamma-secretase interactome and validation of its association with tetraspanin-enriched microdomains.

Comment by:  Michael Wolfe, ARF Advisor
Submitted 23 October 2009 Posted 23 October 2009

This is an excellent study by the De Strooper lab, using a biochemical approach to identify proteins that associate with the γ-secretase complex. The work was rigorously done, with important controls to identify interactions specific to γ-secretase (e.g., parallel purification of the presenilin-like protease SPPL3). The authors confirm several proteins previously reported to interact with γ-secretase, such as TMP21, β-catenin and Rab11, further strengthening confidence in their method. Most interesting was the identification of tetraspanin proteins, which are important in many basic cellular activities, including formation of certain lipid raft-like microdomains. Indeed, γ-secretase components co-distribute with tetraspanin proteins in a sucrose density gradient.

Knockdown of certain associated tetraspanin-web proteins by RNAi led to modest but significant decreases in amyloid-β-protein levels and increases in APP C-terminal fragments that are γ-secretase substrates. Conversely, overexpression can lead to increased amyloid production....  Read more


  Related Paper: Analysis of the gamma-secretase interactome and validation of its association with tetraspanin-enriched microdomains.

Comment by:  Kumar Sambamurti
Submitted 26 October 2009 Posted 27 October 2009
  I recommend this paper

This represents a careful and significant study with clean results. It probably explains why γsecretase loses activity in Triton-X100 and helps in a more thorough functional characterization of the enzyme.

View all comments by Kumar Sambamurti

  Related Paper: Neurodegeneration in an Abeta-induced model of Alzheimer's disease: the role of Cdk5.

Comment by:  Takaomi Saido, ARF Advisor
Submitted 14 November 2009 Posted 17 November 2009
  I recommend this paper
Comments on Related News
  Related News: Nicastrin—A DAPper Role in γ-Secretase

Comment by:  Michael Wolfe, ARF Advisor
Submitted 19 August 2005 Posted 19 August 2005

This is an excellent study from the lab of Gang Yu, the original discoverer of nicastrin as a presenilin partner needed for γ-secretase activity when he was with Peter St. George-Hyslop in Toronto. In his new lab at UT Southwestern, Yu has nailed down an essential role for nicastrin in substrate recognition. To date, virtually nothing has been known about the specific biochemical role of nicastrin in γ-secretase activity. Nicastrin (NCT) is needed for assembly and maturation of the protease complex, including presenilin endoproteolysis into N-terminal fragment (NTF) and C-terminal fragment (CTF) subunits, and the NCT transmembrane domain is critical for these events. However, all the action (substrate binding and catalysis) has so far appeared to be taking place on presenilin. Recent work from our lab (Kornilova et al., 2005) located a substrate docking site at the interface between the two presenilin subunits, at a site distinct from the active site, which is also located at the NTF/CTF interface. The implication is that...  Read more

  Related News: Nicastrin—A DAPper Role in γ-Secretase

Comment by:  Bart De Strooper, ARF Advisor
Submitted 22 August 2005 Posted 23 August 2005

This is an excellent paper.

View all comments by Bart De Strooper

  Related News: Nicastrin—A DAPper Role in γ-Secretase

Comment by:  Vincent Marchesi, ARF Advisor
Submitted 22 August 2005 Posted 23 August 2005

The strength of this paper is the imaginative use of carefully crafted recombinant peptides to study a complicated process that is difficult to approach using conventional cell biological techniques. But one also has to keep in mind that no "native" molecules are actually studied under in vivo conditions. Recombinant C99 peptides are often studied as a more accessible form of the amyloid-β precursor protein (AβPP), the physiological substrate of γ-secretase, and when they are expressed in living cells, one can be reasonably confident that they are mimicking the endogenous molecules. But a consideration in this study is whether they also behave the same way in detergent extracts. Following cleavage by β-secretases, the natural C99 peptides are likely to be dimers in situ, possibly sequestered in lipid raft-like domains, and still attached to an elaborate cytoskeletal network in the adjacent cytoplasm. We have no idea how recombinant-derived peptides are arranged in detergent extracts. If they exist as small micelles, as is likely, are they sticky? Do they bind...  Read more

  Related News: Nicastrin—A DAPper Role in γ-Secretase

Comment by:  Stefan Lichtenthaler
Submitted 24 August 2005 Posted 24 August 2005

It has been known for a while that the ectodomain of type I membrane proteins needs to be proteolytically trimmed before the proteins can be further processed by γ-secretase. This led to the speculation that γ-secretase—and more specifically, the nicastrin subunit within the complex—must somehow be able to act as a molecular ruler and measure the length of the ectodomain of the γ-secretase substrates. Just how this can happen remained unclear. The elegant and convincing work by Shah and colleagues shows that, in fact, nicastrin can act as the molecular ruler. Their appealing model proposes that nicastrin sticks out of the membrane like a crane, binds the substrate, and shifts it to its docking or processing site in the γ-secretase complex. The free N-terminus of a substrate protein seems to be the primary determinant for recognition. Thus, nicastrin should be able to bind substrates regardless of their primary sequence—as long as they have a short ectodomain and contain a transmembrane domain. This model fits well with previous data by us and...  Read more

  Related News: Nicastrin—A DAPper Role in γ-Secretase

Comment by:  Jacob Mack
Submitted 19 August 2005 Posted 30 August 2005

I find this article very informative, however, it is merely educational. While I find it interesting, it is not by finding every molecular binding site and protein involved in AD pathogenesis that we will get us closer to a cure. I love molecular and cellular mechanisms of life... in the words of the great pilot D.P. Davies: "let's get on with it."

View all comments by Jacob Mack
  Submit a Comment on this News Article
Cast your vote and/or make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password  
*Confirm Password  
Remember my Login and Password?  

I recommend the Primary Papers

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
Print this page
Email this page
Alzforum News
Follow on Twitter
Text size
Share & Bookmark
ADNI Related Links
ADNI Data at LONI
ADNI Information
DIAN
Foundation for the NIH
AddNeuroMed
neuGRID
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2010 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad